Skip to main content

Table 4 Incidence of Peripheral Neuropathy during Treatment Cycles

From: Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients

< 70 Years (n = 14)
Cycles 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Grade1 3 4 6 7 9 8 7 6 6 5 2 2 2 1 1 0 0
Grade2 0 1 1 1 1 2 0 1 1 2 4 3 2 1 1 1 0
Grade3 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1
n 14 13 12 11 11 11 9 8 7 7 6 6 4 2 2 2 1
70 Years (n = 8)
Grade1 1 4 6 5 4 4 6 4 4 2 2 1 1 0 0 0 0
Grade2 1 1 0 0 1 1 0 1 0 2 1 1 1 1 0 0 0
Grade3 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
n 8 8 8 7 6 6 6 5 5 4 3 2 2 2 1 0 0
  1. Grades of adverse events were defined according to NCI-CTC v3.0
  2. *P values were calculated with the use of Fisher's exact probability test.